Dan Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dan Yi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chunjiang Wang
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China
4 shared publications - Linli Sun
Department of General Surgery The Third Xiangya Hospital Central South University Changsha China
3 shared publications - Weijin Fang
Department of Pharmacy The Third Xiangya Hospital Central South University Changsha China
3 shared publications - Wei Sun
Department of Pharmacy The Third Xiangya Hospital Central South University Changsha China
2 shared publications - Cuifang Wu
Department of Pharmacy, The Third Xiangya Hospital Central South University Changsha China
1 shared publication - Yanhong Su
Department of Pharmacy Yinan County People's Hospital Linyi China
1 shared publication
Latest Publications
- 5 April 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (5) , 1295-1300
Analysis of the clinical characteristics of insulin autoimmune syndrome induced by alpha‐lipoic acid
What is known and objective Alpha‐lipoic acid (ALA) is widely used as a dietary supplement and antiageing agent. Insulin autoimmune syndrome (IAS) is the most serious adverse reaction reported with the use of ALA. The purpose of this study was to explore the clinical characteristics of ALA‐induced IAS and provide a scientific reference for clinical diagnosis, treatment and prevention. Methods We collected literature on IAS cases induced by ALA for retrospective analysis in Chinese and English. Results and discussion The median age of 37 patients (28 females and 9 males) was 61 years (range 32–82). The symptoms occurred at night and in the early morning (60.7%), in the late postprandial period (50.0%) or after fasting (35.7%), within hours in some patients and up to 2 months in others after stopping ALA or during medication treatment. Autonomic nervous system symptoms (81.1%) and neurological hypoglycaemia (64.9%) are the main clinical manifestations of hypoglycaemia. The blood glucose concentration at the onset of hypoglycaemia was 2.19 mmol/L (median, range 1.09–3.52), the insulin concentration was ≥100 μIU/ml (94.6%), and the C‐peptide concentration was ≤20 ng/ml (83.3%). Testing for IgG insulin autoantibodies (IAAs) was positive in 37 patients. Pancreatic imaging was unremarkable on computed tomography (CT), magnetic resonance imaging (MRI) and abdominal sonography. Hypoglycaemia disappeared within 5 days to 8 months after withdrawing ALA alone or using corticosteroid treatment. IAA turned negative in 7 months (median; range 2–36). Follow‐up showed no recurrent hypoglycaemic episodes at 7.25 months (median; range 1–36). What is new and conclusion ALA‐induced IAS is a clinically rare autoimmune disease with hypoglycaemia that occurs during medication treatment or after drug withdrawal that should be treated promptly.
- 5 April 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (5) , 1295-1300
Analysis of the clinical characteristics of insulin autoimmune syndrome induced by alpha‐lipoic acid
What is known and objective Alpha‐lipoic acid (ALA) is widely used as a dietary supplement and antiageing agent. Insulin autoimmune syndrome (IAS) is the most serious adverse reaction reported with the use of ALA. The purpose of this study was to explore the clinical characteristics of ALA‐induced IAS and provide a scientific reference for clinical diagnosis, treatment and prevention. Methods We collected literature on IAS cases induced by ALA for retrospective analysis in Chinese and English. Results and discussion The median age of 37 patients (28 females and 9 males) was 61 years (range 32–82). The symptoms occurred at night and in the early morning (60.7%), in the late postprandial period (50.0%) or after fasting (35.7%), within hours in some patients and up to 2 months in others after stopping ALA or during medication treatment. Autonomic nervous system symptoms (81.1%) and neurological hypoglycaemia (64.9%) are the main clinical manifestations of hypoglycaemia. The blood glucose concentration at the onset of hypoglycaemia was 2.19 mmol/L (median, range 1.09–3.52), the insulin concentration was ≥100 μIU/ml (94.6%), and the C‐peptide concentration was ≤20 ng/ml (83.3%). Testing for IgG insulin autoantibodies (IAAs) was positive in 37 patients. Pancreatic imaging was unremarkable on computed tomography (CT), magnetic resonance imaging (MRI) and abdominal sonography. Hypoglycaemia disappeared within 5 days to 8 months after withdrawing ALA alone or using corticosteroid treatment. IAA turned negative in 7 months (median; range 2–36). Follow‐up showed no recurrent hypoglycaemic episodes at 7.25 months (median; range 1–36). What is new and conclusion ALA‐induced IAS is a clinically rare autoimmune disease with hypoglycaemia that occurs during medication treatment or after drug withdrawal that should be treated promptly.
- 29 October 2020
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (2) , 470-475
Analysis of the clinical characteristics of insulin autoimmune syndrome induced by methimazole
What is known and Objective The number of case reports of insulin autoimmune syndrome (IAS) induced by methimazole (MMI) is increasing. The purpose of this study is to explore the clinical characteristics and provide a scientific reference for clinical diagnosis, treatment and prevention. Methods The literature on IAS cases and case series induced by MMI in Chinese and English was collected for retrospective analysis. Results and discussion A total of 106 patients (males 33, females 73) were described in the Chinese and English literature. The median age of patients with IAS induced by MMI was 37 years (range 15‐76) occurring during both regular and irregular MMI therapy or after resumption of medication. The onset of symptoms occurred at night or early morning, within days in some and up to 6 months in others; the symptoms were neuropathic in 65.31% and related to the autonomic nervous system in 33.67%. Blood glucose concentration in samples presumably taken during the hypoglycaemic phase was 1.7 mmol/L (median; range 0.03‐4.7); insulin concentrations were elevated ≥100 mU/L (ref range) and associated with low C‐peptide levels (<10 μg/L; ref range). Tests for IgG insulin autoantibodies (IAA) were positive in 104 patients (98.02%) and negative in two patients (1.98%). The 75‐g oral glucose tolerance test (OGTT) showed impaired glucose tolerance and diabetic curves. Pancreatic imaging was unremarkable on computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound. Withdrawal of MMI alone or with corticosteroid treatment reduced hypoglycaemic episodes within days to 3 months. IAA decreased and became negative in 3 months (median; range 1‐12). Follow‐up showed no recurrent hypoglycaemic episodes at 5 months (median; range 1‐60). What is new and Conclusion Methimazole‐induced IAS is a clinically rare autoimmune disease with hypoglycaemia that occurs during medication treatment that should be treated promptly.
- 29 October 2020
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (2) , 470-475
Analysis of the clinical characteristics of insulin autoimmune syndrome induced by methimazole
What is known and Objective The number of case reports of insulin autoimmune syndrome (IAS) induced by methimazole (MMI) is increasing. The purpose of this study is to explore the clinical characteristics and provide a scientific reference for clinical diagnosis, treatment and prevention. Methods The literature on IAS cases and case series induced by MMI in Chinese and English was collected for retrospective analysis. Results and discussion A total of 106 patients (males 33, females 73) were described in the Chinese and English literature. The median age of patients with IAS induced by MMI was 37 years (range 15‐76) occurring during both regular and irregular MMI therapy or after resumption of medication. The onset of symptoms occurred at night or early morning, within days in some and up to 6 months in others; the symptoms were neuropathic in 65.31% and related to the autonomic nervous system in 33.67%. Blood glucose concentration in samples presumably taken during the hypoglycaemic phase was 1.7 mmol/L (median; range 0.03‐4.7); insulin concentrations were elevated ≥100 mU/L (ref range) and associated with low C‐peptide levels (<10 μg/L; ref range). Tests for IgG insulin autoantibodies (IAA) were positive in 104 patients (98.02%) and negative in two patients (1.98%). The 75‐g oral glucose tolerance test (OGTT) showed impaired glucose tolerance and diabetic curves. Pancreatic imaging was unremarkable on computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound. Withdrawal of MMI alone or with corticosteroid treatment reduced hypoglycaemic episodes within days to 3 months. IAA decreased and became negative in 3 months (median; range 1‐12). Follow‐up showed no recurrent hypoglycaemic episodes at 5 months (median; range 1‐60). What is new and Conclusion Methimazole‐induced IAS is a clinically rare autoimmune disease with hypoglycaemia that occurs during medication treatment that should be treated promptly.
- 10 July 2020
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 45 (6) , 1320-1324
Analysis of clinical characteristics of tigecycline‐induced acute pancreatitis
What is known and Objective The purpose of this study is to explore the clinical characteristics of tigecycline‐induced acute pancreatitis. Methods We searched the PubMed/Medline, Web of Knowledge, OVID, Elsevier, Springer Link, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and Chinese VIP databases from 2005 and identified 19 studies of tigecycline‐induced acute pancreatitis involving a total of 22 patients for inclusion in a retrospective analysis. Results and Discussion The median (range) age of 22 patients with acute pancreatitis was 58 years (range 9‐83). Overall, the median (range) time of symptom onset was 6.5 days (range 2‐28), or 6 days (range 2‐14) and 6 days (range 3‐28) in patients with or without a loading dose of tigecycline, respectively. Symptoms included nausea, vomiting and abdominal distension (73%) and abdominal pain (73%); 90% (18/20) of patients developed mild acute pancreatitis (MAP), and 10% (2/20) developed severe acute pancreatitis (SAP). Computed tomography (CT) scans showed oedematous infiltrate in 56% (10/18) of cases and acute pancreatitis in 28% (5/18) of cases. The median (range) level of lipase and amylase was 936U/L (range 382‐4089) and 588U/L (range 312‐1166), respectively. The median (range) time to recovery of symptoms was 4 days (range 1‐10), and the time for recovery of pancreatic enzymes to the normal range was 5 days (range 1‐30) after the withdrawal of tigecycline in all patients. What is new and Conclusion Clinicians should be particularly mindful of clinical signs and symptoms, the level of serum pancreatic enzymes and abdominal CT images in order to monitor the development of pancreatitis when using tigecycline.
- 10 July 2020
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 45 (6) , 1320-1324
Analysis of clinical characteristics of tigecycline‐induced acute pancreatitis
What is known and Objective The purpose of this study is to explore the clinical characteristics of tigecycline‐induced acute pancreatitis. Methods We searched the PubMed/Medline, Web of Knowledge, OVID, Elsevier, Springer Link, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and Chinese VIP databases from 2005 and identified 19 studies of tigecycline‐induced acute pancreatitis involving a total of 22 patients for inclusion in a retrospective analysis. Results and Discussion The median (range) age of 22 patients with acute pancreatitis was 58 years (range 9‐83). Overall, the median (range) time of symptom onset was 6.5 days (range 2‐28), or 6 days (range 2‐14) and 6 days (range 3‐28) in patients with or without a loading dose of tigecycline, respectively. Symptoms included nausea, vomiting and abdominal distension (73%) and abdominal pain (73%); 90% (18/20) of patients developed mild acute pancreatitis (MAP), and 10% (2/20) developed severe acute pancreatitis (SAP). Computed tomography (CT) scans showed oedematous infiltrate in 56% (10/18) of cases and acute pancreatitis in 28% (5/18) of cases. The median (range) level of lipase and amylase was 936U/L (range 382‐4089) and 588U/L (range 312‐1166), respectively. The median (range) time to recovery of symptoms was 4 days (range 1‐10), and the time for recovery of pancreatic enzymes to the normal range was 5 days (range 1‐30) after the withdrawal of tigecycline in all patients. What is new and Conclusion Clinicians should be particularly mindful of clinical signs and symptoms, the level of serum pancreatic enzymes and abdominal CT images in order to monitor the development of pancreatitis when using tigecycline.
- 14 May 2020
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 45 (4) , 722-728
Retrospective analysis of the clinical characteristics of adefovir dipivoxil–induced Fanconi’s syndrome in the Chinese population
What is known and objective To explore the clinical characteristics of adefovir dipivoxil–induced Fanconi's syndrome in the Chinese population and provide a reference for rational drug use in the clinic. Methods By searching the CNKI, Wanfang, Chinese VIP, PubMed/MEDLINE, Web of Knowledge, Ovid, Elsevier and SpringerLink databases during 1 January 2008 to 31 December 2019, 78 studies of ADV‐induced Fanconi's syndrome involving a total of 110 patients were collected and analysed retrospectively. Results and discussion Prolonged usage of adefovir dipivoxil at low doses to treat hepatitis B might cause Fanconi's syndrome as the first symptom, especially for use over 12 months.The main clinical manifestation was bone pain accompanied by hypophosphataemia, elevated alkaline phosphatase (ALP), urine glycosuria and urine protein. X‐rays and bone mineral density (BMD) examinations were mainly used to characterized osteoporosis. The patients had pain relief within 1 week to 1 month, and the biochemical indicators returned to normal within from 2 to 4 months. What is new and conclusion Sufficient attention is required before and during exposure to long‐term ADV therapy. The clinical picture, laboratory and radiograph alterations are important clues for ADV‐induced Fanconi's syndrome.
- 14 May 2020
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 45 (4) , 722-728
Retrospective analysis of the clinical characteristics of adefovir dipivoxil–induced Fanconi’s syndrome in the Chinese population
What is known and objective To explore the clinical characteristics of adefovir dipivoxil–induced Fanconi's syndrome in the Chinese population and provide a reference for rational drug use in the clinic. Methods By searching the CNKI, Wanfang, Chinese VIP, PubMed/MEDLINE, Web of Knowledge, Ovid, Elsevier and SpringerLink databases during 1 January 2008 to 31 December 2019, 78 studies of ADV‐induced Fanconi's syndrome involving a total of 110 patients were collected and analysed retrospectively. Results and discussion Prolonged usage of adefovir dipivoxil at low doses to treat hepatitis B might cause Fanconi's syndrome as the first symptom, especially for use over 12 months.The main clinical manifestation was bone pain accompanied by hypophosphataemia, elevated alkaline phosphatase (ALP), urine glycosuria and urine protein. X‐rays and bone mineral density (BMD) examinations were mainly used to characterized osteoporosis. The patients had pain relief within 1 week to 1 month, and the biochemical indicators returned to normal within from 2 to 4 months. What is new and conclusion Sufficient attention is required before and during exposure to long‐term ADV therapy. The clinical picture, laboratory and radiograph alterations are important clues for ADV‐induced Fanconi's syndrome.